Business Editors/Health & Medical Writers
FORT LAUDERDALE, Fla.--(BW HealthWire)--April 10, 2002
ANDRX CORPORATION - Andrx Group (Nasdaq: ADRX) today announced that the United States Food and Drug Administration (FDA) has approved the marketing of its Abbreviated New Drug Application (ANDA) for both strengths (10 and 20 mEq) of potassium chloride extended release tablets.
Potassium chloride is bioequivalent to Schering-Plough Corporation's brand name product, K-Dur(R), and is used as a treatment for cardiovascular disease and is a potassium supplement typically in cardiovascular disease. Andrx plans to market its product immediately.
Andrx Corporation is a specialty pharmaceutical company engaged in the formulation and commercialization of oral controlled-release generic and brand pharmaceuticals utilizing its proprietary drug delivery technologies.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including those risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission.
This release and additional information about Andrx Corporation are also available on the Internet at: http://www.andrx.com.
COPYRIGHT 2002 Business Wire
COPYRIGHT 2002 Gale Group